- Report
- July 2025
- 482 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- July 2025
- 168 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- January 2025
- 54 Pages
Global
From €2193EUR$2,499USD£1,898GBP
- Report
- July 2025
- 262 Pages
Global
From €6139EUR$6,995USD£5,312GBP
- Report
- November 2024
- 525 Pages
Global
From €4212EUR$4,799USD£3,644GBP
- Report
- November 2024
- 799 Pages
Global
From €4212EUR$4,799USD£3,644GBP
- Report
- November 2024
- 240 Pages
Global
From €2106EUR$2,400USD£1,822GBP
- Report
- May 2025
- 170 Pages
Global
From €4081EUR$4,650USD£3,531GBP
- Report
- April 2025
- 162 Pages
Global
From €4081EUR$4,650USD£3,531GBP
- Report
- March 2025
- 211 Pages
Global
From €4081EUR$4,650USD£3,531GBP
- Report
- September 2024
- 97 Pages
Global
From €4256EUR$4,850USD£3,683GBP
- Report
- February 2025
- 683 Pages
Global
From €4344EUR$4,950USD£3,759GBP
- Report
- August 2024
- 317 Pages
Global
From €3686EUR$4,200USD£3,189GBP
- Report
- September 2024
- 156 Pages
Global
From €4081EUR$4,650USD£3,531GBP
- Report
- May 2025
- 195 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 183 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 198 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 184 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 186 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 186 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP

The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells.
ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases.
The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more